$11.68
0.78% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US91678A1079
Symbol
UPB
Sector
Industry

Upstream Bio Stock price

$11.68
+2.18 22.95% 1M
-9.84 45.72% 6M
-4.76 28.95% YTD
-5.32 31.29% 1Y
-5.32 31.29% 5Y
-5.32 31.29% 10Y
-5.32 31.29% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
+0.09 0.78%
ISIN
US91678A1079
Symbol
UPB
Sector
Industry

Key metrics

Market capitalization $628.31m
Enterprise Value $196.93m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 66.98
P/S ratio (TTM) P/S ratio 213.71
P/B ratio (TTM) P/B ratio 1.41
Revenue (TTM) Revenue $2.94m
EBIT (operating result TTM) EBIT $-109.78m
Free Cash Flow (TTM) Free Cash Flow $-100.34m
Cash position $431.38m
EPS (TTM) EPS $-1.93
P/E forward negative
P/S forward 387.31
EV/Sales forward 121.39
Show more

Is Upstream Bio a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,840 stocks worldwide.

Upstream Bio Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Upstream Bio forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Upstream Bio forecast:

Buy
100%

Financial data from Upstream Bio

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2.94 2.94
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 24 24
-
815%
- Research and Development Expense 89 89
-
3,019%
-110 -110
-
-3,730%
- Depreciation and Amortization 0.13 0.13
-
4%
EBIT (Operating Income) EBIT -110 -110
-
-3,734%
Net Profit -104 -104
-
-3,526%

In millions USD.

Don't miss a Thing! We will send you all news about Upstream Bio directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Upstream Bio Stock News

Neutral
GlobeNewsWire
7 days ago
WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, on Sunday, June 15, 2025.
Neutral
GlobeNewsWire
8 days ago
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on ...
Neutral
GlobeNewsWire
23 days ago
WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer.
More Upstream Bio News

Company Profile

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Head office United States
CEO E. Sutherland
Website upstreambio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today